IP Library Granted Patent US 10,251,839
Granted Patent B2
US 10,251,839 · App. 12/017,932 · Granted Apr 9, 2019

Lipid vesicles derived from olive oil fatty acids

Inventors: Nadya Lawrence (Cape May, NJ); Rosemarie Lorenzo (Sicklerville, NJ)
Assignee: IGI Laboratories, Inc.
A61K9/1272
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,251,839
App. No.
12/017,932
Granted
Apr 9, 2019
Kind
B2
Abstract

Novel lipid vesicle compositions comprising lipids derived from olive oil fatty acids known as olivates, methods of their preparation, and methods of their use in cosmetics, food, dermatologics, and pharmaceuticals.

Claims (67)

1. A composition comprising paucilamellar lipid vesicles, wherein the lipid vesicles comprise:

(a) a lipid phase comprising

(i) about 2.3% to about 7.0% by weight of polyethylene glycol 4-olivate;

(ii) about 0.3% to about 0.7% by weight of a sterol;

(iii) about 5% to about 15% by weight of one or more oils; and

(b) an aqueous phase comprising about 75% to about 95% by weight of water,

wherein the lipid vesicles in the composition are homogeneous and stable at 25° C. for at least one week.

2. The composition of claim 1 , wherein said aqueous phase further comprises an antimicrobial agent.

3. The composition of claim 1 , wherein said sterol is selected from the group consisting of cholesterol, cholesterol derivatives, cholesterol salts, cholesterol esters, ethoxylated cholesterol, hydrocortisone, phytosterol, avocado unsaponifiables and mixtures thereof.

4. The composition of claim 1 , wherein said one or more oils is a triglyceride selected from the group consisting of caprylic triglyceride, capric triglyceride, and mixtures thereof.

5. The composition of claim 1 , wherein said one or more oils is a hydrocarbon.

6. The composition of claim 1 , wherein said hydrocarbon is mineral oil.

7. The composition of claim 1 , wherein said lipid phase further comprises a nonionic detergent.

8. The composition of claim 7 , wherein said nonionic detergent is selected from the group consisting of polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (20) sorbitan trioleate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate, and mixtures thereof.

9. The composition of claim 2 , wherein said antimicrobial agent is a composition comprising propylene glycol, diazolidinyl urea, methylparaben, and propylparaben.

10. The composition of claim 1 , wherein the pH is between about 2 to about 8.

11. The composition of claim 1 , wherein said paucilamellar lipid vesicles have 2-10 lipid bilayers surrounding an amorphous central cavity.

12. The composition of claim 7 , wherein the sterol is polyoxyethylene (20) sorbitan monooleate, the sterol is cholesterol, and the oil comprises caprilic triglyceride and capric triglyceride.

13. The composition of claim 1 , wherein the sterol is cholesterol and the oil is mineral oil.

14. The composition of claim 1 , wherein the lipid vesicles comprise:

(a) a lipid phase comprising,

(i) about 2.3% by weight of polyethylene glycol 4-olivate;

(ii) about 1.0% by weight of polyoxyethylene (20) sorbitan monooleate;

(iii) about 0.3% by weight of cholesterol; and

(iii) about 5.0% by weight of a mixture of caprilic triglyceride and capric triglyceride; and

(b) an aqueous phase comprising,

(i) about 90.4% by weight of water; and

(ii) about 1.0% of an antimicrobial agent comprising propylene glycol, diazolidinyl urea, methylparaben and propylparaben,

wherein the pH of the composition is about 6.2-6.3.

15. The composition of claim 1 , wherein the lipid vesicles comprise:

(a) a lipid phase comprising,

(i) about 4.5% by weight of polyethylene glycol 4-olivate;

(ii) about 1.0% by weight of polyoxyethylene (20) sorbitan monooleate;

(iii) about 0.5% by weight of cholesterol; and

(iv) about 10.0% by weight of a mixture of caprilic triglyceride and capirc triglyceride; and

(b) an aqueous phase comprising,

(i) about 83% by weight of water; and

(ii) about 1% of an antimicrobial agent comprising propylene glycol, diazolidinyl urea, methylparaben and propylparaben,

wherein the pH of the composition is about 6.2-6.3.

16. The composition of claim 1 , wherein the lipid vesicles comprise:

(a) a lipid phase comprising,

(i) about 6.5% by weight of polyethylene glycol 4-olivate;

(ii) about 1.0% by weight of polyoxyethylene (20) sorbitan monooleate;

(iii) about 0.7% by weight of cholesterol; and

(iv) about 15.0% by weight of a mixture of caprilic triglyceride and capirc triglyceride; and

(b) an aqueous phase comprising,

(i) about 75.8% by weight of water; and

(ii) about 1.0% of an antimicrobial agent comprising propylene glycol, diazolidinyl urea, methylparaben and propylparaben,

wherein the pH of the composition is about 6.2-6.3.

17. The composition of claim 1 , wherein the lipid vesicles comprise:

(a) a lipid phase comprising,

(i) about 2.3% by weight of polyethylene glycol 4-olivate;

(ii) about 0.3% by weight of cholesterol; and

(iii) about 5.0% by weight of mineral oil; and

(b) an aqueous phase comprising,

(i) about 91.4% by weight of water; and

(ii) about 1.0% of an antimicrobial agent comprising propylene glycol, diazolidinyl urea, methylparaben and propylparaben,

wherein the pH of the composition is about 6.2-6.3.

18. The composition of claim 1 , wherein the lipid vesicles comprise:

(a) a lipid phase comprising,

(i) about 4.5% by weight of polyethylene glycol 4-olivate;

(ii) about 0.5% by weight of cholesterol; and

(iii) about 5.0% by weight of mineral oil; and

(b) an aqueous phase comprising,

(i) about 89.0% by weight of water; and

(ii) about 1.0% of an antimicrobial agent comprising propylene glycol, diazolidinyl urea, methylparaben and propylparaben,

wherein the pH of the composition is about 6.2.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Feb 14, 2025
From: TEXAS CAPITAL BANK, AS ADMINISTRATIVE AGENT
To: PAI HOLDINGS, LLC
Reel/Frame 070218/0760 →
SECURITY INTEREST Recorded Feb 13, 2025
From: PAI HOLDINGS, LLC; VERTICE PHARMA, LLC
To: MIDCAP FINANCIAL TRUST, AS COLLATERAL AGENT
Reel/Frame 070215/0050 →
SECURITY INTEREST Recorded Sep 4, 2024
From: PAI HOLDINGS, LLC
To: TEXAS CAPITAL BANK, AS ADMINISTRATIVE AGENT
Reel/Frame 068481/0232 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2022
From: TELIGENT, INC.
To: PAI HOLDINGS, LLC
Reel/Frame 059082/0834 →
RELEASE OF SECURITY INTEREST Recorded Dec 17, 2018
From: CANTOR FITZGERALD SECURITIES
To: TELIGENT, INC; IGEN, INC.; TELIGENT PHARMA, INC
Reel/Frame 047800/0356 →
SECURITY INTEREST Recorded Dec 17, 2018
From: TELIGENT, INC.; IGEN, INC.
To: ARES CAPITAL CORPORATION
Reel/Frame 047800/0532 →
SECURITY INTEREST Recorded Dec 17, 2018
From: TELIGENT, INC; IGEN, INC.
To: ACF FINCO I LP
Reel/Frame 047800/0477 →
NOTICE OF GRANT Recorded Jun 1, 2018
From: TELIGENT, INC.; IGEN, INC.; TELIGENT PHARMA, INC.
To: CANTOR FITZGERALD SECURITIES, AS COLLATERAL AGENT
Reel/Frame 046286/0946 →
RELEASE OF SECURITY AGREEMENT RECORDED 3/16/09, R/F 02239/0570 Recorded May 20, 2009
From: LIFE SCIENCES OPPORTUNITIES FUND II, L.P.; LIFE SCIENCES OPPORTUNITIES FUND (INSTITUTIONAL) II, L.P.
To: IGI LABORATORIES INC.; IMMUNOGENETICS, INC.
Reel/Frame 022708/0091 →
SECURITY AGREEMENT Recorded Mar 16, 2009
From: IGI LABORATORIES, INC.; IMMUNOGENETICS, INC.
To: LIFE SCIENCES OPPORTUNITIES FUND II, L.P.; LIFE SCIENCES OPPORTUNITIES FUND (INSTITUTIONAL) II, L.P.
Reel/Frame 022399/0576 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2008
From: LAWRENCE, NADYA; LORENZO, ROSEMARIE
To: IGI LABORATORIES, INC.
Reel/Frame 020776/0668 →
Continuity (1)
Related Publication 20090186074A1 · Jul 23, 2009